Filing Flows › Acadia Pharmaceuticals (ACAD) › Q2 2026
Acadia Pharmaceuticals (ACAD) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Acadia Pharmaceuticals (ACAD) reported revenue of $308M for the second quarter 2026 (Q2 2026), +16% from a year earlier and +15% from the quarter before. Operating margin was 12.3%, net earnings $31.5M (10.2% of revenue).
Acadia Pharmaceuticals, Q2 2026: revenue $308M (+16% year over year), operating margin 12.3%, net earnings $31.5M, operating cash flow $101M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $308M | +15% | +16% |
| Operating profit | $37.8M | — | +17% |
| Net earnings | $31.5M | +766% | +18% |
| Operating cash flow | $101M | +197% | +58% |
| Free cash flow | $95.7M | +233% | +50% |
What changed
Revenue was $308.0M in Q2 2026, up 16% year over year and up 15% from the previous quarter.
Operating profit was $37.8M, a 12.3% margin (unchanged year over year). Of the extra revenue versus Q2 2025, 13% reached operating profit, above the 12% margin then. Total costs grew 16% against revenue growth of 16%. The fastest-growing cost line was Cost of revenue (+37%). Net earnings were $31.5M, up 18% year over year. The effective tax rate was 32.2%.
Operating cash flow was $100.8M (up 58% year over year), 320% of net earnings. Non-cash charges added back $3.2M of depreciation and amortization and $16.9M of share-based compensation. Working capital and other items added $49.2M. Capital expenditures of $5.1M left free cash flow of $95.7M.
Questions
What was Acadia Pharmaceuticals' revenue in the second quarter 2026?
Acadia Pharmaceuticals (ACAD) reported revenue of $308M for the second quarter 2026 (Q2 2026), +16% from a year earlier and +15% from the quarter before.
Was Acadia Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $37.8M (12.3% of revenue) and net earnings $31.5M.